Navigation Links
Arete Therapeutics Initiates Phase IIa Clinical Trial for AR9281, a Novel s-EH Inhibitor to Treat Type 2 Diabetes
Date:2/10/2009

HAYWARD, Calif., Feb. 10 /PRNewswire/ -- Arete Therapeutics Inc. today announced the initiation of a Phase IIa clinical trial for AR9281, an orally- administered soluble epoxide hydrolase (s-EH) inhibitor being developed for the treatment of type 2 diabetes. S-EH is an enzyme involved in the metabolism of arachidonic acid, a key signaling molecule implicated in diabetes, hypertension and inflammatory disorders.

"Our AR9281 Phase II clinical trial program breaks new ground in two key areas. This is the first clinical study of a s-EH inhibitor in patients, and the first study designed to establish proof of concept that s-EH inhibition modulates glucose metabolism or blood pressure in patients with impaired glucose tolerance and hypertension," said James Sabry, M.D., Ph.D., President and Chief Executive Officer of Arete Therapeutics. "AR9281 has demonstrated an excellent safety profile and activity in multiple animal models of type 2 diabetes, and has the advantage of inhibiting a novel drug target that differentiates it from currently marketed diabetes medications. With this promising drug profile, AR9281 has the potential to provide safe and effective therapy for patients with type 2 diabetes either as monotherapy or in combination with existing treatment regimens."

The Phase IIa multicenter, double-blind, placebo-controlled study will enroll 150 pre-diabetic patients with impaired glucose tolerance, mild obesity and mild to moderate hypertension. All patients enrolled in the study will be treatment-naïve for type 2 diabetes medications. The trial will evaluate two schedules of AR9281 and placebo using a parallel design to determine the feasibility of twice-a-day dosing. Each patient will receive 28 days of treatment. Endpoints for the trial include safety, tolerability, reduction of blood pressure and various measures of glucose and lipid metabolism, with results expected in the first quarter of 2010.'/>"/>

SOURCE Arete Therapeutics Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. CareTech Solutions Executive to Conduct Presentation on Creating a Healthy Revenue Cycle at AHIMA Convention and Exhibit
2. Arete Therapeutics Initiates Phase 1 Clinical Trial For AR9281 as a First-in-Class Antihypertensive Agent
3. Arete Therapeutics Appoints Donald Santel to Board of Directors
4. CareTech Solutions Service Desk Equals Help Desk Plus
5. Nationally Recognized Diabetes Specialist Dr. Steven Edelman to Provide Educational Articles on Diabetes to MyCareTeam's Website Community
6. CareTech Solutions Named Best in KLAS for Extensive IT Outsourcing Services
7. EnovateIT Partners with CareTech Solutions to Create a Custom Product for Crittenton Hospital Medical Center, One of the Nation's Most Wired Hospitals
8. Prime Therapeutics Receives TIPPS Certification
9. Adams Respiratory Therapeutics to Celebrate 10th Anniversary of its Incorporation on September 12
10. Transition Therapeutics Announces Fiscal 2007 Year End Financial Results
11. Lorus Therapeutics announces election of three new Directors and appoints a new Chairman
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... , ... August 31, 2015 , ... When it comes to undergoing a hair transplant, ... of the head. Adding more volume to the hair on top of the scalp, ... who have a good amount of donor hair on other areas of their head. , ...
(Date:8/31/2015)... ... August 31, 2015 , ... In an article ... expert guest author addressed the topic of treating back pain caused by a disrupted ... were shown to slightly improve physical function in patients suffering from a herniated disk, ...
(Date:8/31/2015)... ... August 31, 2015 , ... India Network Foundation, ... InstantQuote ” tool, which summarizes all available plans, plan maximums, pre-existing condition coverage ... designed to help India Network members make an informed decision regarding the care ...
(Date:8/31/2015)... CA (PRWEB) , ... August 31, 2015 , ... ... center management, recently opened registration for the company’s second Introduction to Hyperbaric Medicine ... held October 15-18, 2015 aboard the Queen Mary Hotel in Long Beach, CA. ...
(Date:8/31/2015)... ... 31, 2015 , ... The Lisle family law firm of Momkus McCluskey, ... by his peers to earn a “Leading Lawyers” distinction. , The ... state of Illinois. The nomination process is based on statewide peer survey nominations and ...
Breaking Medicine News(10 mins):Health News:Body Hair Transplants to Help Achieve a Full Head of Hair 2Health News:Article on Steroid Use for Back Pain Highlights the Effectiveness of Surgery in Treating Disk Pain, says Dr. Seyed M. Rezaian 2Health News:India Network proudly launches the new InstantQuote tool to help choose right visitor health insurance with pre-existing conditions to US bound visitors 2Health News:Registration Opens for Wound Care Advantage’s Second UHMS Approved 40-Hour Introduction to Hyperbaric Medicine Course 2Health News:Registration Opens for Wound Care Advantage’s Second UHMS Approved 40-Hour Introduction to Hyperbaric Medicine Course 3Health News:Registration Opens for Wound Care Advantage’s Second UHMS Approved 40-Hour Introduction to Hyperbaric Medicine Course 4Health News:DuPage County Family Law Attorney Named Illinois Leading Lawyer 2
... be Driven by Increasing Use of Established Agents That Include,Avastin, Erbitux, ... ... Resources, WALTHAM, Mass., June 10 ... for pharmaceutical and,healthcare issues, finds that the monoclonal antibodies (MAbs) drug ...
... /Xinhua-PRNewswire-FirstCall/ -- Linkwell,Corporation (Linkwell) (OTC Bulletin Board: ... healthcare related disinfectants in China,announced today that ... and also,Vice President of the Shanghai Disinfection ... into some of the,worst disaster areas of ...
... Sky One,Medical, Inc. (Amex: CSY ) (,China ... of pharmaceutical, medicinal and,diagnostic products in China, today ... 2008 periods., China Sky One Medical, Inc. ... over the first quarter of 2008 to $19.5 ...
... Two Organizations Announce Plans for Celebrating World Blood ... 10 To increase national,and global appreciation of ... Recruitment Professionals (ADRP) are partnering together to,encourage their ... on June 14. This specific day marks the ...
... for current quarter and beyond, PURCHASE, N.Y., ... ), a developer and marketer of nutritional supplements ... health,enhance memory and address chronic joint pain, today ... the omega-3 direct response market,by launching Iceland Health(R) ...
... June 10 NBTY, Inc. (NYSE:,NTY) (http://www.NBTY.com ), ... announced it submitted the best and highest,bid at an ... of substantially,all of the assets of Leiner Health Products, ... entered into an amended and,restated Asset Purchase Agreement (the ...
Cached Medicine News:Health News:The Monoclonal Antibodies Drug Market for the Treatment of Cancer Will More Than Double to $16.7 Billion By 2016 2Health News:Linkwell Corporation Disinfection Epidemic Prevention Teams Enter into Sichuan Earthquake Area 2Health News:Linkwell Corporation Disinfection Epidemic Prevention Teams Enter into Sichuan Earthquake Area 3Health News:China Sky One Medical, Inc. Announces Guidance for Second Quarter and Full Year 2008 2Health News:China Sky One Medical, Inc. Announces Guidance for Second Quarter and Full Year 2008 3Health News:AABB and the Association of Donor Recruitment Professionals Partner to Recognize Blood Donors Worldwide 2Health News:AABB and the Association of Donor Recruitment Professionals Partner to Recognize Blood Donors Worldwide 3Health News:AABB and the Association of Donor Recruitment Professionals Partner to Recognize Blood Donors Worldwide 4Health News:Nutrition 21 Launches Iceland Health(R) Advanced Memory Formula via Direct Response Channel 2Health News:Nutrition 21 Launches Iceland Health(R) Advanced Memory Formula via Direct Response Channel 3Health News:Nutrition 21 Launches Iceland Health(R) Advanced Memory Formula via Direct Response Channel 4Health News:Nutrition 21 Launches Iceland Health(R) Advanced Memory Formula via Direct Response Channel 5Health News:NBTY Announces Agreement to Purchase Leiner Health Products 2Health News:NBTY Announces Agreement to Purchase Leiner Health Products 3Health News:NBTY Announces Agreement to Purchase Leiner Health Products 4Health News:NBTY Announces Agreement to Purchase Leiner Health Products 5
(Date:8/31/2015)... Aug. 31, 2015  The departments of Drug and ... at Gaudenzia Concept 90 to raise awareness for International ... in Pennsylvania and help more ... on recovery through the Building Bridges to Recovery ... dying every day to a disease that is fully ...
(Date:8/31/2015)... FLINT, Mich. , Aug. 31, 2015  Diplomat Pharmacy, ... pharmacy, has announced that Phil Hagerman , Chairman & ... four upcoming investor conferences. Mr. Hagerman and ... 2015 Healthcare Conference in Boston on ... Mr. Hagerman and Mr. Whelan are also scheduled to participate ...
(Date:8/31/2015)... 2015  Soligenix, Inc. (OTCQB: SNGX) (Soligenix ... products that address unmet medical needs in the ... it has completed enrollment of the additional subjects, ... earlier this year, into the company,s Phase 2 ... defense regulator (IDR) and is being evaluated as ...
Breaking Medicine Technology:Pennsylvania Departments of Drug & Alcohol Programs and Health Kick-off Second Annual Building Bridges to Recovery Initiative 2Diplomat to Participate in Upcoming Investor Conferences 2Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 2Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 3Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 4Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 5Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 6
... Mass., Oct. 26, 2011 Idenix Pharmaceuticals, Inc. (NASDAQ: ... financial results for the third quarter of 2011 on Wednesday, ... Idenix management will host a conference call at 4:30 p.m. ... financial results for the third quarter of 2011 and provide ...
... 2011 /PRNewswire-iReach/ -- UBM Medica today announced ... features content dedicated to the latest developments in the ... other major rheumatologic diseases. (Photo:   http://photos.prnewswire.com/prnh/20111026/CG93984 ... have altered the landscape of rheumatology and the quality ...
Cached Medicine Technology:Idenix to Host Conference Call Discussing Third Quarter and Nine Month 2011 Financial Results and Announces Presentations at the American Association for the Study of Liver Diseases Meeting (AASLD) 2UBM Medica's Musculoskeletal Network Highlights Changing Rheumatologic Landscape 2UBM Medica's Musculoskeletal Network Highlights Changing Rheumatologic Landscape 3
Suction Catheter Kits with Sterile Saline (Bottle)...
Clear plastic sleeve envelopes a plastic suction catheter. Sleeve slides over exudate to reduce potential clinician contact....
The rubber, whistle tip catheter with thumb valve has two side eyes to help minimize trauma....
Gentle-Flo® Vactrol® Connector., ,Indications For Usage: ,Removal of secretions from respiratory tract....
Medicine Products: